Cresco Labs Future Growth
Future criteria checks 0/6
Cresco Labs is forecast to grow earnings and revenue by 61.7% and 1.9% per annum respectively while EPS is expected to grow by 68.3% per annum.
Key information
61.7%
Earnings growth rate
68.3%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 1.9% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 733 | -26 | 52 | 70 | 3 |
| 12/31/2025 | 717 | -22 | 43 | 76 | 8 |
| 12/31/2024 | 721 | -69 | 97 | 130 | 8 |
| 9/30/2024 | 726 | -67 | 75 | 100 | N/A |
| 6/30/2024 | 735 | -172 | 59 | 91 | N/A |
| 3/31/2024 | 747 | -155 | 48 | 92 | N/A |
| 12/31/2023 | 756 | -176 | 1 | 59 | N/A |
| 9/30/2023 | 767 | -339 | -1 | 65 | N/A |
| 6/30/2023 | 786 | -234 | -23 | 50 | N/A |
| 3/31/2023 | 806 | -211 | -44 | 25 | N/A |
| 12/31/2022 | 825 | -212 | -67 | 19 | N/A |
| 9/30/2022 | 842 | -65 | -38 | 53 | N/A |
| 6/30/2022 | 848 | -326 | -62 | 34 | N/A |
| 3/31/2022 | 841 | -318 | -114 | -2 | N/A |
| 12/31/2021 | 806 | -320 | -83 | 14 | N/A |
| 9/30/2021 | 750 | -360 | -99 | -3 | N/A |
| 6/30/2021 | 687 | -73 | -74 | 20 | N/A |
| 3/31/2021 | 573 | -105 | -25 | 43 | N/A |
| 12/31/2020 | 463 | -102 | -97 | -8 | N/A |
| 9/30/2020 | 345 | -76 | -149 | -34 | N/A |
| 6/30/2020 | 231 | -98 | -186 | -70 | N/A |
| 3/31/2020 | 168 | -64 | -185 | -57 | N/A |
| 12/31/2019 | 124 | -43 | -121 | -25 | N/A |
| 9/30/2019 | 101 | -20 | -94 | -29 | N/A |
| 6/30/2019 | 78 | -14 | -67 | -20 | N/A |
| 3/31/2019 | 57 | -12 | -53 | -16 | N/A |
| 12/31/2018 | 41 | -2 | -40 | -10 | N/A |
| 9/30/2018 | 28 | 0 | -26 | -4 | N/A |
| 6/30/2018 | 19 | 1 | N/A | -7 | N/A |
| 3/31/2018 | 13 | 1 | N/A | -6 | N/A |
| 12/31/2017 | 10 | -3 | N/A | -5 | N/A |
| 12/31/2016 | 3 | -8 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6CQ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6CQ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6CQ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6CQ's revenue (1.9% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: 6CQ's revenue (1.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6CQ's Return on Equity is forecast to be high in 3 years time